AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Radiopharm’s shares gained more than 4% in the early hours of 23 November post a new update on Phase II imaging trial in brain metastases.
- Additional data related to F-18 Pivalate in Phase II imaging trial on brain metastases showed maximum standardised uptake within lesions.
- Radiopharm’s CEO stated that obtaining a quality image implies another positive step for the potential of the Pivalate technology for the company.
Radiopharm Theranostics (ASX:RAD) has provided an upbeat update concerning F-18 Pivalate (RAD 101), its lead product candidate for brain metastases.
The company stated that Imperial College London has provided further data related to the Phase 2a imaging trial of the compound in patients with brain metastases.
High contrast images seen at 60 minutes after the injection of Pivalate showed the maximum standardised uptake within lesions. The results were significantly different compared to the mean.
Image source: Company update
Image description: High contrast images seen after Pivalate injection
As per the company’s CEO Riccardo Canevari, this is a promising indication and yet another positive step for the potential of the Pivalate technology for Radiopharm.
More to come…
Shares of Radiopharm were trading at AU$0.120 with an uptick of around 4.347% in the early hours of 23 November 2022.
